Market revenue in 2023 | USD 31.5 million |
Market revenue in 2030 | USD 0.0 million |
Growth rate | -100% (CAGR from 2023 to 2030) |
Largest segment | Gene therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy, Tissue Engineered, Others (Combined ATMPs, for example biodegradable matric or scaffold) |
Key market players worldwide | Bluebird bio Inc, Novartis AG ADR, UniQure NV, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Vericel Corp, Organogenesis Holdings Inc Class A, Spark Therapeutics, Celgene, Kolon Industries, Medipost, Pharmicell |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to advanced therapy medicinal products market will help companies and investors design strategic landscapes.
Gene therapy was the largest segment with a revenue share of 52.06% in 2023. Horizon Databook has segmented the Argentina advanced therapy medicinal products market based on gene therapy, cell therapy, tissue engineered, others (combined atmps, for example biodegradable matric or scaffold) covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina advanced therapy medicinal products market , including forecasts for subscribers. This country databook contains high-level insights into Argentina advanced therapy medicinal products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account